HK Pharmaceuticals, Inc. Obtains Patent For Combinatorial Ribozyme Library Technology
10/19/2005 5:11:11 PM
HK Pharmaceuticals™, Inc. today announced that it has obtained a patent from the Canadian Patent Office (CA 2319112) entitled "Use of Ribozymes for Functionating Genes." This core patent covers processes for combinatorial ribozyme libraries and technologies to turn off principal pathways within cells, or inactivate genes, to visualize genetic and phenotypic attributes of selected genes coding for proteins of therapeutic interest. A corresponding US patent has been allowed and is expected to be issued soon.
HK Pharmaceuticals’ method uses ribozymes, molecules of RNA with enzyme-like properties, to cleave specific messenger RNA sequences to silence the activity of selected genes resulting in reduced or eliminated expression of the respective proteins. Because many diseases are caused by the activity of specific genes, the ability to silence such genes selectively is a valuable tool for drug target validation, pathway mapping and the elucidation of a drug’s mechanism of action. The experiments can take as little as a few days compared to the several months it takes to knock out a single gene in mice.
comments powered by